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Abstract  17 
Whilst there is substantial evidence of cardiac troponin (cTnI) appearance during or 18 
subsequent to endurance exercise the database with short duration, high intensity exercise is 19 
extremely limited.  The reproducibility of any exercise-related cTnI response is unclear at this 20 
point.  Consequently, we recruited 18 healthy young male adults who undertook two all-out 21 
30 s cycle sprints separated by 7 days.  cTnI, blood lactate and catecholamine concentrations 22 
were measured before, immediately after and 24 hr after each bout.  Cycle performance, heart 23 
rate and blood pressure responses to exercise were also recorded. Whilst cycle performance 24 
was modestly elevated in the second trial (6.5% increase in peak power output) there was no 25 
difference in the cardiovascular, lactate or catecholamine response to the two cycle trials.  26 
cTnI was not significantly elevated from baseline through recovery (Trial 1: 0.06±0.04 ng.ml
-
27 
1
, 0.05±0.04 ng.ml
-1
, 0.03±0.02 ng.ml
-1
 Trial 2: 0.02±0.04 ng.ml
-1
, 0.04±0.03 ng.ml
-1
, 28 
0.05±0.06 ng.ml
-1
) in either trial. Very small within subject changes were not significantly 29 
correlated between the two trials (r=0.06; p>0.05). We can conclude that short duration, high 30 
intensity exercise does not elicit a clinically relevant response in cTnI and any small 31 
alterations likely reflect the underlying biological variability of cTnI measurement within the 32 
participants.  33 
 34 
  35 
Introduction 36 
Recent scientific literature is replete with observations of elevated cardiac biomarkers during 37 
and after prolonged endurance exercise [1, 2, 3, 4].  Different cardiac biomarkers reflect 38 
different pathological and/or physiological processes but most attention in the sports 39 
medicine literature has been paid to the exercise-related appearance of cardiac troponins 40 
(cTnI and/or cTnT).  cTnI/T are recognised as highly tissue-specific biomarkers of myocyte 41 
cell insult [5] and are important in clinical decision making when acute cardiac events are 42 
suspected [6].  An elevation in cTn either during or after exercise has, consequently, 43 
generated both interest and concern in athletes, scientists and clinicians [4].  44 
 45 
An exercise-associated elevation in cTnI and/or cTnI has been reported after endurance 46 
events lasting a couple of hours [7] through to multiple days [8].  The mechanism(s) 47 
associated with exercise-related appearance of cTnI or T have not been proven but likely 48 
relate to the unremitting cardiovascular work and associated changes in metabolic milieu of 49 
the cardiomycocytes [4]. Most available data related to exercise-associated increases in cTnI 50 
or cTnT have been produced from field-based studies with simple pre-post blood draws [4].  51 
This has limited our ability to interpret this data and the exact role that exercise plays.  A 52 
unique study was completed by Middleton et al. (2008) [9] whereby 9 marathon runners 53 
completed a treadmill-based marathon run with blood taken every 30 min.  This study 54 
demonstrated an elevation in cTnT in every single runner with some changes noted as early 55 
as 30 min after the start of exercise. In another study by the same group, cTnI was elevated in 56 
most runners completing a high intensity, steady state 30 min run [10].   Taken together these 57 
data would suggest that exercise-associated elevations of cTn are likely very common and 58 
may occur very quickly with exercise.  Despite this we still require additional data to 59 
determine if a cTn-positive response is produced in response to exercise per se.  Neither is it 60 
clear whether very high exercise intensity (with concomitant shortened durations) may 61 
mediate cTn release [4].  Finally, to date there is limited evidence as to whether the cTn 62 
response to any exercise bout is a reproducible phenomenon. 63 
 64 
Consequently, the aim of the current study was to assess; a) the appearance of cTnI after a 65 
short bout (30 s) of “all-out” intense exercise, and b) to determine the stability of any exercise 66 
related cTnI release in response to repeated bouts of high intensity exercise separated by 7 67 
days recovery. 68 
  69 
Materials and methods 70 
Subjects and design 71 
Eighteen apparently healthy, physically active, male university students volunteered 72 
to participate (mean±SD age: 23±2.0 yr; body mass: 75.3±11 kg; stature 175.8±5.7 cm. The 73 
study was approved by the University Ethics Committee and all participants provided written 74 
informed consent form. All participants were full familiarised to the exercise test. The study 75 
design was a repeated measures approach to biomarker assessment before and after 2 high 76 
intensity exercise trials, separated by 7 days. For six weeks prior to data collection, and 77 
throughout the study, participants maintained normal physical activity and dietary habits and 78 
refrained from macro and micro-nutrient supplementation and/or the use of pharmaceutical 79 
agents.  Repeated assessments of cardiac biomarkers were made before, immediately after 80 
and 24 h after each exercise bout. 81 
 82 
Baseline measures 83 
At baseline body mass, stature and body composition was determined using a 84 
calibrated balanced weighing scales (Seca, UK), stadiometer (Seca, UK) and underwater 85 
weighing procedures, respectively. Body density was assessed as described previously [11]. 86 
Relative body fat was estimated from body density [12]. Residual lung volume was measured 87 
using the simplified oxygen re-breathing method [13]. Fat free mass (FFM) was determined 88 
by subtracting fat mass from total body mass.   89 
 90 
 The Acute Exercise Test 91 
Participants performed 2 all-out 30 s cycle ergometer tests (Monark, 864, Monark-Crescent 92 
AB, Varberg, Sweden).  A force velocity test was performed one week prior to the 30s cycle 93 
ergometer test to determine optimal resistive forces based on total body mass (TBM) and fat free mass 94 
(FFM). Briefly, the test consisted of six short maximal sprints (6-8 s) against randomly assigned 95 
resistive forces (70, 75, 80, 85, 90 and 95 g.kg
-1
). Successive exercise bouts were separated by a 5 min 96 
rest period. The resistive force that produced the highest PPO value for both TBM and FFM protocol 97 
was used in the 30s test. Reliability of the optimal resistive force obtained for both TBM and FFM 98 
protocol was determined using test retest methods. The order of the two 30s tests were 99 
randomised and separated by 7 days. The cycle ergometer was set-up and calibrated in the 100 
same way for all tests [14]. Saddle heights were adjusted to accommodate partial knee flexion 101 
of between 170° to 175° (with 180° denoting a straight leg position) during the down stroke 102 
and were consistent between repeated tests. Feet were firmly supported by toe clips and 103 
straps. All subjects were instructed to remain seated during the test and were verbally 104 
encouraged to perform maximally. All participants performed a standardised 5 min warm up 105 
prior to experimental data collection [15]. Participants were given a rolling start at 60 rpm for 106 
a 5 s period prior to resistive force application. On the command 'go', the subjects began to 107 
pedal maximally, the resistive force applied simultaneously, and data capture initiated. 108 
Indices of performance were calculated from flywheel revolutions using an inertia corrected 109 
computer program [14]. Data transfer was made possible using a mounted sensor unit and 110 
power supply attached to the fork of the ergometer located opposite the flywheel. The 111 
sampling frequency of the sensor was 18.2 Hz.  Validity of the cycle ergometer as a test of 112 
muscle power has been reported as r = 0.93 [16]. Heart rate was recorded throughout exercise 113 
using a short range telemetry system (Sport Tester 3000, Polar Electro Finland).  Peak power 114 
output (PPO), the highest l-s value of power attained during each 30-s sprint as well as mean 115 
power output (MPO), the average power output for the 30-s period, were recorded for each 116 
trial. A fatigue index, the drop in power from a maximal to a minimal value over the 30 s was 117 
expressed as a percentage and total work done was estimated across the 30 s sprint. 118 
 119 
Blood Sampling and analysis 120 
 Duplicate blood samples were collected at the same time of day and by the same 121 
investigator in all trials in an attempt to control for biological and between subject variation 122 
[17]. In an attempt to control for plasma volume changes, all resting samples were taken 123 
following 30 min of supine rest. The immediate post exercise samples were taken with 124 
subjects placed in a supine position on a clinical couch to minimise the risk of fainting. 125 
Capillary blood samples were collected from the right ear lobe and were analysed 126 
immediately for Haematocrit (Hawksley Micro haematocrit reader, Sussex, UK), 127 
haemoglobin (Haemocue, Sussex, UK) and blood lactate concentration (Analox P-LM5, 128 
London, UK).  Changes in plasma volume were calculated from haematocrit and 129 
haemoglobin using the equations of Dill and Costill (1974) [18].  This data was used to adjust 130 
absolute data of biomarkers for any alterations in plasma volume. 131 
At the same time venous blood samples were collected from an antecubital forearm 132 
vein using the Vacutainer System (Becton Dickinson, Rutherford, NJ, USA) and placed 133 
immediately on ice. Samples were centrifuged at 3,500 rpm for 10 min. Serum was then 134 
extracted and placed into plastic storage containers and stored at -80°C.   135 
 136 
Adrenaline and noradrenaline concentrations were determined using the Gilson 137 
ASTED.XL (Anachem; Luton, Beds, UK), a fully automated sample processing system, with 138 
an improved sample handling system that included dialysis and sample clean-up on a strong 139 
cation trace-enrichment cartridge. The catecholamines were separated by reverse phase ion-140 
pair chromatography. Calibrations were run every tenth and controls, every fifth sample. 141 
Coefficients of variation ranged between 1.1% and 9.3%. 142 
 143 
Cardiac Troponin I (cTnI) concentrations were determined using the Chiron 144 
Diagnostics ACS: 180 ® Automated Chemiluminescence Systems (Medfield, MA, U.S.A.). 145 
The detection limit for cTnI was set at 0.06 ug.L
-1
. The coefficient of variation was 146 
established at 3.5%.  147 
 148 
 Statistical Analysis  149 
Data were analysed using a computerised statistical package (SPSS Version 2, 150 
Chigaco, USA) using parametric statistics. Significance was set at the P < 0.05 level. 151 
Confirmation that all dependent variables were normally distributed was assessed via 152 
repeated Kolmogorov-Smirnov tests. Changes in exercise performance and peak HR data 153 
between trials were compared using repeated measures ANOVA.  Blood borne parameters 154 
and cTnI data were compared via repeated measures 2-way ANOVA (TIME: pre; 155 
immediately; and 24 h post exercise; TRIAL: TBM, FFM). Following simple main and 156 
interaction effects, Bonferroni-corrected paired samples t-tests were applied to make 157 
posteriori comparisons of the effect of time at each level of the trial factor.  The delta change 158 
in cTnI from baseline to immediately post-exercise was compared between trials using a 159 
intra-class correlation test.  160 
 161 
Results 162 
Values for performance data and peak heart rate generated during the study for the 163 
two 30-s all out cycling trials are presented in Table 1. Although there was a small but 164 
significantly higher PPO with the FFM trial (c. 6.5%, P < 0.05), all other performance test 165 
data were not different between trials (P > 0.05). Resting HR (68 beats.min
-1
) was the same 166 
prior to both trials and peak HR attained was not different between trials. There was a 167 
significant PVL between baseline and end-exercise (P < 0.05) that was not different between 168 
trials (P > 0.05; Table 2), with a return to baseline at 24 h post-test in both trials.  This data 169 
was used to correct data for blood borne parameters and biomarkers. Of note the blood lactate 170 
concentrations rose with exercise (P < 0.05) and declined to baseline at 24 h post trial but 171 
these changes were similar between trials (P > 0.05; Table 2).  Biomarkers of sympathetic 172 
neural activation, adrenaline and noradrenaline, were elevated post-exercise in both trials (P 173 
< 0.05; Table 2) and returned to baseline at 24 h post exercise. Again the kinetics of 174 
adrenaline and noradrenaline change with all-out 30-s exercise was consistent between trials 175 
(P < 0.05).  176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
 184 
 185 
 186 
 187 
Table 1.  Exercise performance and HR data for the cohort over both 30 s trials. 188 
Parameter Trial Mean ± SD 
PPO (W) 1-TBM 953 ± 111 
2-FFM 1020 ± 130 * 
Time to PPO (s) 1-TBM 4.1 ± 3.1 
2-FFM 3.5 ± 1.5 
MPO (W)  1-TBM 535 ± 81 
2-FFM 512 ± 86 
FI (%) 1-TBM 42 ± 8 
2-FFM 38 ±10 
Total Work (J) 1-TBM 16050 ± 1828 
2-FFM 15369 ± 1975 
Peak HR (beats.min
-1
) 1-TBM 177 ± 8 
2-FFM 175 ± 5 
TBM-total body mass, FFM-fat free mass, PPO-peak power output, MPO-mean power output, FI-fatigue index, 189 
HR-heart rate, * significantly different from the other trial (P < 0.05).  190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
Table 2. Blood borne biomarker data for both short duration high intensity cycle trials 198 
Parameter Trial Baseline Immediate Post-Ex 24 h Post-Ex 
PVL (%) 1-TBM - -12.2 ± 5.8 4.3 ± 10.0 
2-FFM - -12.6 ± 6.9 5.1 ± 6.2 
BLa (mmol.l
-1
)* 1-TBM 0.5 ± 0.7 9.0 ± 1.2  0.6 ± 0.6 
2-FFM 1.1 ± 0.9 9.3 ± 1.4 0.7 ± 0.8 
A (nmol.l
-1
)* 1-TBM 0.3 ± 0.1 2.8 ± 1.6 0.3 ± 0.1 
2-FFM 0.2 ± 0.1 3.3 ± 1.9 0.3 ± 0.1 
NA (nmol.l
-1
)* 1-TBM 1.3 ± 0.4 19.1 ± 7.9 1.5 ± 0.5 
2-FFM 1.7 ± 0.4 20.0 ± 9.6 1.3 ± 0.4 
PVL-plasma volume loss, BLa-blood lactate concentration, A-adrenaline, NA-noradrenaline, Ex-exercise, *-199 
significant main effect of time, but no significant main effect of trial or interaction. 200 
 201 
Mean cohort data for cTnI are presented in Figure 1. In both trials there was no 202 
significant main effect of sample time, trial or interaction effect.  Cohort data can mask small 203 
individual changes and consequently we plotted delta cTnI from baseline to immediately 204 
post-exercise from both trials in Figure 2.  This Figure demonstrates that any individual 205 
change is very small and largely unpredictable from trial to trial (r=-0.02; P > 0.05).  206 
 207 
 208 
 209 
Figure 1.  Group mean data for cTnI in Trial 1 and 2 at baseline, immediately post-exercise 210 
and 24 h post-exercise. 211 
 212 
Figure 2.  Scatterplot of delta cTnI responses from pre-exercise to post-exercise for trial 1 and 213 
2. 214 
Discussion 215 
The key novel finding from this study is that short duration, high intensity cycling bouts (30 216 
s) does not elicit a statistically or clinically significant increase in circulating cTnI during 217 
immediate or late (24 hr post) recovery. Any small individual changes in response to exercise 218 
are not consistent between trials and likely reflects the small biological variance in the cTnI 219 
assay within a young, healthy cohort.  220 
 221 
The extant sports medicine literature is replete with descriptive evidence of a rise in cTnI or 222 
cTnT during or after bouts of endurance exercise [4].  This phenomenon has been reported in 223 
different participant groups from the elite athlete to relatively untrained “weekend warrior” 224 
[e.g. 7, 19], from young adolescents to those in later life [e.g. 20, 21], across a range of 225 
exercise bouts [22, 23]. What has characterised nearly all studies to date has been the 226 
employment of endurance activity as it has been assumed that any cTn release with exercise 227 
is due to some mechanism associated with the unremitting haemodymanic or metabolic stress 228 
of prolonged activity on the heart. Recently, two studies have shed new and interesting 229 
insights into exercise-related cTn appearance.  Firstly, Middleton et al. (2008) [22] assayed 230 
for cTn every 30 min during a treadmill-based marathon run and reported early (at 30 min) 231 
elevation of cTn is some runners and an exercise-related cTn rise in all runners at some point 232 
during the marathon.  The same group then employed a high intensity 30 min run and 233 
observed a rise in cTn in most participants [10].  Taken together it was hypothesised that a 234 
cTn rise with exercise was potentially an inevitable phenomenon that would likely be 235 
physiological in nature.  The current study was conceived as an extension to the work of 236 
Middleton et al. (2008) [22] and Shave et al. (2010b) [10] to determine if any exercise (per 237 
se), even 30 s of high intensity cycling, could act as a stimulus to induce cTn changes in the 238 
circulation.  Whilst exercise may be a potent stimulus for cTn appearance in the systemic 239 
circulation, the lack of a statistical or clinically significant rise in cTn after a 30s all-out cycle 240 
trial in the current study would suggest that the total volume of exercise undertaken (30 s all-241 
out) placed insufficient stress on the heart.  Despite a rapid acceleration of HR with 30 s of all 242 
out cycling, there is a subsequent quick deceleration of HR suggesting that the total 243 
myocardial work and oxygen demand is very low in comparison to previous studies that have 244 
employed endurance exercise, over many hours, days and even weeks [4]. 245 
 246 
A secondary aim from this study was to determine if the cTn response to a short duration, 247 
high intensity cycle trial was consistent and repeatable if the exposure was repeated after 7 248 
days.  The repeatability of the exercise-related cTn response has received scant attention [20] 249 
but may be insightful when addressing the potential impact or mechanisms involved in cTn 250 
appearance with exercise.  At one level the cTn response to the exercise intervention 251 
employed was highly consistent as there was no significant rise in cTn after both cycling 252 
trials.  This consistency in a “null” response adds to the apparent repeatability in the “cTn-253 
positive” response to exercise in a mixed adult/adolescent running study [20]. A secondary, 254 
within subject analysis in the current study assessed the consistency of the very small changes 255 
in cTn observed post-exercise.  Not surprisingly the correlation of delta responses was very 256 
low (r=0.06) given the small absolute and relative changes.  This likely provides some insight 257 
into the very low levels of biological variability of this cTn assay in these participants’ 258 
undertaking short bouts of activity. 259 
 260 
The implications from this study are straightforward.  Short bursts of high intensity activity 261 
do not seem to result in an elevation in cTn either immediately or during later recovery from 262 
exercise suggesting this type of exercise bout does not activate the mechanism(s) required to 263 
elicit a statistically or clinically meaningful cTn response.  Within the applied sports 264 
medicine setting the appearance of large cTn increase (above clinical cut-offs 0.2 ng.ml
-1
) in 265 
any participants or athletes with a recent history of exercise of less than 30 min should raise a 266 
potential red flag for further clinical investigation. 267 
  268 
As with all studies there as some limitations of note that should be followed up in on-going 269 
studies. The data in the current study pertain only to young, healthy male participants.  Given 270 
that there may be different exercise-cTn responses in different participant populations this 271 
study should be replicated in broader groups (age, sex, fitness status).  Future work may 272 
employ blood samples in recovery to provide conclusive evidence of a lack cTn response to 273 
short bouts of physical activity. 274 
   275 
In conclusion, a short duration, high intensity cycle trial does not result in an elevation of 276 
cTnI immediately post-exercise or later during recovery (24 hr).  The lack of a cTn response 277 
was consistent over two cycling trials suggesting the overall response was repeatable.  Small 278 
between subject variance in cTn response to the exercise stimulus was clinically meaningless 279 
and likely reflects a low level of biological variability in this assay in the current participants.  280 
 281 
 282 
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